Analysis of whether adagrasib (Krazati) is a chemotherapy drug and how it differs from traditional chemotherapy

Adagrasiib (Krazati) is an oral targeted drug that is a selective KRAS G12C inhibitor. It is mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. It achieves anti-tumor effects by specifically inhibiting the KRAS G12C signaling pathway and blocking cancer cell proliferation and survival. Because it targets specific genetic mutations, it is a precision targeted therapy drug rather than a traditional chemotherapy drug.

Traditional chemotherapy drugs usually kill rapidly proliferating tumor cells by interfering with DNA replication, inhibiting cell division or inducing apoptosis. This type of drug has a wide range of effects, affecting both cancer cells and normal, rapidly dividing cells. Therefore, it is often accompanied by systemic adverse reactions such as hair loss, bone marrow suppression, nausea and vomiting. By targeting the specific KRAS G12C mutation, adagrasib only works in cancer cells carrying this mutation, causing relatively little damage to normal cells and being better tolerated.

Adagrasib is mainly used for KRAS G12C mutation-positive late-stage NSCLC patients. Its efficacy depends on the patient’s genetic status, while traditional chemotherapy does not rely on gene mutations and has a wider range of applications. However, the efficacy is relatively limited, especially in patients with specific gene mutations. The effect is not as significant as targeted drugs. Targeted drugs can usually provide higher objective response rates (ORR) and longer progression-free survival (PFS), while reducing systemic toxic and side effects and improving patients' quality of life.

In clinical applications, adagrasib is often used as a single agent in targeted treatment regimens, and can also be used in combination with other drugs in some studies to enhance the efficacy. Patients need to undergo genetic testing to confirm that the KRAS G12C mutation is positive before use to ensure the drug is targeted. Compared with traditional chemotherapy, adagrasib's treatment plan is more precise and its side effects are more controllable. However, liver function, blood routine and possible tumor response still need to be monitored to ensure safety and optimal efficacy.

Reference link:https://www.drugs.com